Teja Thorat

685 total citations
27 papers, 475 citations indexed

About

Teja Thorat is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and General Health Professions. According to data from OpenAlex, Teja Thorat has authored 27 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Economics and Econometrics, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in General Health Professions. Recurrent topics in Teja Thorat's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Cystic Fibrosis Research Advances (10 papers) and Healthcare Policy and Management (8 papers). Teja Thorat is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Cystic Fibrosis Research Advances (10 papers) and Healthcare Policy and Management (8 papers). Teja Thorat collaborates with scholars based in United States, United Kingdom and Netherlands. Teja Thorat's co-authors include Peter J. Neumann, James D. Chambers, Joshua T. Cohen, Joshua A. Salomon, Alyssa Bilinski, Lisa J. McGarry, Michael J. Cangelosi, Junhee Pyo, J. Edgar Anderson and Yue Zhong and has published in prestigious journals such as PLoS ONE, PLoS Medicine and The Journal of Pediatrics.

In The Last Decade

Teja Thorat

26 papers receiving 463 citations

Peers

Teja Thorat

GHP

PRM

PPCH

HEMAT

Edward C. Mansley United States

Richéal Burns United Kingdom

Felipe Roitberg Brazil

Hannah K Mitchell United States

Mary Ann Baily United States

Colin Rodgers United Kingdom

Marlene Gyldmark Switzerland

Chalachew Alemayehu Australia

Barbara Jagels United States

Chukwuemeka Umeh United States

Edward C. Mansley United States

Teja Thorat

209 ×0.8

88 ×0.7

GHP

48 ×0.6

PRM

37 ×0.6

PPCH

8 ×0.2

HEMAT

Citations per year, relative to Teja Thorat Teja Thorat (= 1×) peers Edward C. Mansley

Countries citing papers authored by Teja Thorat

Since Specialization

Citations

This map shows the geographic impact of Teja Thorat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teja Thorat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teja Thorat more than expected).

Fields of papers citing papers by Teja Thorat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teja Thorat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teja Thorat. The network helps show where Teja Thorat may publish in the future.

Co-authorship network of co-authors of Teja Thorat

This figure shows the co-authorship network connecting the top 25 collaborators of Teja Thorat. A scholar is included among the top collaborators of Teja Thorat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teja Thorat. Teja Thorat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gerstein, Maya, et al.. (2025). Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis. PLoS ONE. 20(1). e0317775–e0317775.

Merlo, Christian A., Teja Thorat, Lisa J. McGarry, et al.. (2024). A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis. Pulmonary Therapy. 10(4). 483–494. 2 indexed citations

Merlo, Christian A., Teja Thorat, Maral DerSarkissian, et al.. (2024). Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis. Thorax. 79(10). 925–933. 8 indexed citations

Merlo, Christian A., Lisa J. McGarry, Teja Thorat, et al.. (2024). Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis. Thorax. 79(10). 915–924. 2 indexed citations

Simmonds, Nicholas J., Cornelis K. van der Ent, Carla Colombo, et al.. (2022). VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non–G551D-CFTR gating mutations. Journal of Cystic Fibrosis. 22(1). 124–131. 3 indexed citations

Thorat, Teja, Lisa J. McGarry, Machaon Bonafede, et al.. (2021). Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatric Pulmonology. 56(9). 2833–2844. 14 indexed citations

Thorat, Teja, Lisa J. McGarry, Brendan Limone, et al.. (2021). Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulmonary Therapy. 7(1). 281–293. 6 indexed citations

Suthoff, Ellison, Jochen G. Mainz, D. Cox, et al.. (2019). Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. The Journal of Pediatrics. 215. 164–171.e2. 13 indexed citations

Lavelle, Tara A., David M. Kent, Christine Lundquist, et al.. (2018). Patient Variability Seldom Assessed in Cost-effectiveness Studies. Medical Decision Making. 38(4). 487–494. 18 indexed citations

10.

Bilinski, Alyssa, et al.. (2017). When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Medicine. 14(10). e1002397–e1002397. 66 indexed citations

11.

Chambers, James D., et al.. (2017). Drugs Cleared Through The FDA’s Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process. Health Affairs. 36(8). 1408–1415. 21 indexed citations

12.

Thorat, Teja, et al.. (2016). Qaly Gains in Cancer Compared with Chronic Diseases. Value in Health. 19(3). A9–A10. 2 indexed citations

13.

Chambers, James D., et al.. (2016). Do First-In-Class Drugs Offer Larger Incremental Health Gains Than Next-In-Class Drugs?. Value in Health. 19(7). A464–A464. 1 indexed citations

14.

Thorat, Teja, Pei‐Jung Lin, & Peter J. Neumann. (2015). The State of Cost-Utility Analyses in Asia: A Systematic Review. Value in Health Regional Issues. 6. 7–13. 14 indexed citations

15.

Chambers, James D., et al.. (2015). Fast-Tracking Innovation: A Scorecard for The Fda’s Expedited Review Process. Value in Health. 18(7). A517–A517. 2 indexed citations

16.

Thorat, Teja, et al.. (2015). Understaning Qaly Gains Across Different Types Of Cancers And Cancer-Related Interventions. Value in Health. 18(3). A192–A192. 1 indexed citations

17.

Neumann, Peter J., et al.. (2015). The Changing Face of the Cost-Utility Literature, 1990–2012. Value in Health. 18(2). 271–277. 77 indexed citations

18.

Chambers, James D., et al.. (2015). Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time. Health Affairs. 34(8). 1376–1382. 30 indexed citations

19.

Chambers, JD, et al.. (2014). Do Specialty Drugs Offer Greater Value for Money Than Traditional Drugs?. Value in Health. 17(7). A419–A420. 1 indexed citations

20.

Thorat, Teja, Michael J. Cangelosi, & Peter J. Neumann. (2012). Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry. Journal of Benefit-Cost Analysis. 3(1). 1–9. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact